Premium
Effects of non‐euphoric plant cannabinoids on muscle quality and performance of dystrophic mdx mice
Author(s) -
Iannotti Fabio Arturo,
Pagano Ester,
Moriello Aniello Schiano,
Alvino Filomena Grazia,
Sorrentino Nicolina Cristina,
D'Orsi Luca,
Gazzerro Elisabetta,
Capasso Raffaele,
De Leonibus Elvira,
De Petrocellis Luciano,
Di Marzo Vincenzo
Publication year - 2019
Publication title -
british journal of pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.432
H-Index - 211
eISSN - 1476-5381
pISSN - 0007-1188
DOI - 10.1111/bph.14460
Subject(s) - duchenne muscular dystrophy , skeletal muscle , autophagy , inflammation , mdx mouse , myogenesis , dystrophin , myocyte , cannabidiol , pharmacology , biology , microbiology and biotechnology , endocrinology , medicine , biochemistry , apoptosis , cannabis , psychiatry
Duchenne muscular dystrophy (DMD), caused by dystrophin deficiency, results in chronic inflammation and irreversible skeletal muscle degeneration. Moreover, the associated impairment of autophagy greatly contributes to the aggravation of muscle damage. We explored the possibility of using non-euphoric compounds present in Cannabis sativa, cannabidiol (CBD), cannabidivarin (CBDV) and tetrahydrocannabidivarin (THCV), to reduce inflammation, restore functional autophagy and positively enhance muscle function in vivo.